Heights Capital Management, Inc. recently announced the acquisition of new stake in Intec Pharma Ltd. (NASDAQ:NTEC). This fresh investment now brings its stake to 7.22% valued currently at $2.1 million. In addition, Sabby Capital LLC raised its holdings by 3.52 million to 4.03 million shares. And Armistice Capital LLC has lifted its position by 33.19% or 0.91 million shares – to 3.64 million shares.

With over 1.15 million Intec Pharma Ltd. (NTEC) shares trading Friday and a closing price of $0.30 on the day, the dollar volume was approximately $0.35 million. The shares have shown a positive weekly performance of 2.92% and its price on 08/28/20 gained nearly 2.81%. Currently, there are 78.96M common shares owned by the public and among those 60.13M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for NTEC have a consensus price objective of $0.50. The analysts have set the share’s price value over the next 12 months at a high of $0.50 and a low of $0.50 should the stock experience a downside. Incidentally, analysts’ outlook for the Intec Pharma Ltd. stock is 3.00 for the next 12 months. But an upside of 40.0% will see the stock hit the forecast high price target while mean target price for the stock is $0.50.

Insiders at the company have transacted a total of 3 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 1 of these insider trades were purchases, accounting for 1,000 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 805,951 shares.

Shares of Intec Pharma Ltd. (NASDAQ: NTEC) opened at $0.30, up $0.01 from a prior closing price of $0.29. However, the script later closed the day at $0.30, up 2.81%. The company’s stock has a 5-day price change of 2.92% and -26.83% over the past three months. NTEC shares are trading -40.00% year to date (YTD), with the 12-month market performance down to -58.32% lower. It has a 12-month low price of $0.13 and touched a high of $1.56 over the same period. Currently, 1.15 million shares have been traded, compared to an average intraday trading volume of 9.72 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -16.76%, -14.93%, and -15.12% respectively.

Institutional ownership of Intec Pharma Ltd. (NASDAQ: NTEC) shares accounts for 17.02% of the company’s 78.96M shares outstanding. Mutual fund holders own 2,476.80%, while other institutional holders and individual stakeholders account for 4,445.68% and — respectively.

It has a market capitalization of $23.69M. The earnings-per-share (ttm) stands at -$0.76. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.89% over the week and 9.64% over the month.

Analysts forecast that Intec Pharma Ltd. (NTEC) will achieve an EPS of -$0.04 for the current quarter, -$0.04 for the next quarter and -$0.15 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.05 while analysts give the company a high EPS estimate of -$0.04. Comparatively, EPS for the current quarter was -$0.61 a year ago. Earnings per share for the fiscal year are expected to increase by 85.10%, and 28.60% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Intec Pharma Ltd. (NTEC) as a “Hold” at a consensus score of 3.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 3 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the NTEC, a number of firms have released research notes about the stock. ROTH Capital stated their Neutral rating for the stock in a research note on October 11, 2019, with the firm’s price target at $10-$1. Maxim Group coverage for the Intec Pharma Ltd. (NTEC) stock in a research note released on March 26, 2018 offered a Buy rating with a price target of $12. Ladenburg Thalmann was of a view on February 28, 2018 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on February 26, 2018, issuing a price target of. Oppenheimer on their part issued Outperform rating on September 21, 2017.